General Announcement::DISCLOSURE PURSUANT TO RULE 324(1) OF THE LISTING MANUAL

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
11-Dec-2020 22:15:49
Status
New
Announcement Sub Title
DISCLOSURE PURSUANT TO RULE 324(1) OF THE LISTING MANUAL
Announcement Reference
SG201211OTHRNB2O
Submitted By (Co./ Ind. Name)
GLENMARK PHARMACEUTICALS LIMITED
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
11/12/2020 19:45:00
Description (Please provide a detailed description of the event in the box below)
Reference is made to the Company s U.S.$200,000,000 4.5% cent. Senior Notes due 2021 (ISIN: XS1456577334; Common Code: 1456577334) (the Notes ) issued on 1 August 2016 and listed on the Singapore Exchange Securities Trading Limited (the SGX-ST ). Reference is also made to the Company s announcement dated 9 December 2020 in relation to the redemption of U.S.$182,500,000 in aggregate principal amount of its Notes, representing approximately 91.25% of the aggregate principal amount of the Notes at the time of initial listing.

The Company wishes to announce that the Company had on 11 December 2020 redeemed U.S.$7,500,000 in aggregate principal amount of its Notes, representing approximately 3.75% of the aggregate principal amount of the Notes at the time of initial listing. As on the date of this announcement, U.S.$10,000,000 in aggregate principal amount of Notes remain outstanding.

Attachments

SGX_Announcement_11122020.pdf
Total size =433K